comparemela.com

Latest Breaking News On - Lagundi - Page 13 : comparemela.com

VCO, lagundi, tawa-tawa clinical trials eyed to be completed by June – DOST – Manila Bulletin

Published May 3, 2021, 6:25 PM Clinical trials on the use of the Virgin Coconut Oil (VCO), lagundi (Chinese chaste tree), and tawa-tawa (Euphorbia hirta) as a coronavirus disease (COVID-19) therapeutic or supplement are expected to be completed by June, the Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) said on Monday, May 3. (Manila Bulletin File Photos) DOST-PCHRD Executive Director Dr. Jaime C. Montoya expressed optimism that studies on the herbal medicines as a potential supplement that could help prevent the worsening of condition in patients afflicted with the COVID-19 virus will be concluded next month. “Itong lagundi, tawa-tawa at VCO, sana ay matapos na at ang target po natin ay katapusan ng Hunyo, pero po maraming pag-aaral na nagsisimula rin na bago na iba ibang indikasyon ang tinintingan so maaari na magoverlap (These clinical trials on lagundi, tawa-tawa and VCO, hopefully, they will be completed soon, an

From pandesal to milktea

SunStar From pandesal to milktea FROM PANDESAL TO MILK TEA. General Manager Erwin Galang and Product Manager Irving Vendiola led the opening ceremony of Wow Milk Tea Bar. (Contributed photo) + WOW MilkTea Bar was born from Pampanga s homegrown and well-patronized, Wow Pandesal brand. Established last April 24, 2021, its team rolled out to serve a wide selection of premium-flavored and tea-based drinks at affordable and reasonable prices. “Our mission is not only to serve drinks but to create more opportunities for our franchise partners and employees amidst the pandemic,” said general manager and owner, Erwin Galang. “I am very fortunate to be taken care of by my employment company. And now, it s time to pay it forward through entrepreneurship. Helping and giving source of dignity is our priority,” he added.

DOST braces for immediate completion of Stage 2 lagundi clinical trials

Published April 12, 2021, 3:13 PM The Department of Science and Technology (DOST) is bracing for the immediate completion of the Stage 2 of clinical trials on the use of lagundi (Chinese chaste tree) as a  coronavirus disease (COVID-19) therapeutic or supplement. DOST Secretary Fortunato “Boy” T. de la Peña said on Monday, April 12,  with the inclusion of more trial centers, the lagundi clinical trials will be expedited.  (FLICKR / FILE PHOTO) “In fact, ang pinakamalaking contributor ngayon ng participants ay quarantine centers sa Quezon City. Kaya ang target nila na 200 sa kanilang Stage 2 ay siguro ay in a few weeks ay matatapos na ‘yan (In fact, the biggest contributor of participants now is the quarantine centers in Quezon City. Their 200 target participants for Stage 2 may be competed in a few weeks,” he said during the televised Laging Handa briefing on Monday.

Lagundi trial as COVID-19 treatment nears completion

Lagundi trial as COVID-19 treatment nears completion
cnnphilippines.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnnphilippines.com Daily Mail and Mail on Sunday newspapers.

159 COVID-19 patients to participate in Phase 2 of lagundi clinical trials

Published April 10, 2021, 10:48 AM Over 150 coronavirus disease (COVID-19) patients have been enrolled to participate in the Stage 2 of clinical trials on the use of lagundi (Chinese chaste tree) as a  coronavirus disease (COVID-19) therapeutic or supplement, the Department of Science and Technology (DOST) has reported.  (FLICKR / MANILA BULLETIN) DOST Secretary Fortunato “Boy” T. de la Peña disclosed this during his weekly report on Friday, April 9.  “On the project to evaluate the efficacy and safety of Lagundi tablets in patients without co-morbidities, suspected or with mild COVID-19:  screening and recruitment of participants for stage 2 is ongoing,” he said.  He noted that as of March 26, 2021, the project has enrolled a total of 159 participants from six study sites or quarantine facilities. 

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.